359877-52-4

Basic information

• Product Name: tert-butyl 4-((4-methylphenyl)methyl)aminopiperidine carboxylate
• Synonyms: tert-butyl 4-((4-methylphenyl)methyl)aminopiperidine carboxylate
• CAS NO: 359877-52-4
• Molecular Weight: 304.433
• Mol File: 359877-52-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-((4-methylphenyl)methyl)aminopiperidine carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-((4-methylphenyl)methyl)aminopiperidine carboxylate(359877-52-4)
• EPA Substance Registry System: tert-butyl 4-((4-methylphenyl)methyl)aminopiperidine carboxylate(359877-52-4)

Safety Data

• Hazardous Substances Data: 359877-52-4(Hazardous Substances Data)

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 104-84-7 para-methylbenzylamine 

Downstream Products

• 359878-07-2 N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-4-fluorophenylacetamide 
• 1091681-69-4 4-[benzyloxycarbonyl-(4-methyl-benzyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester 
• 359879-00-8 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-(1-(3-(1,3-dihydro-2H-benzimidazol-2-one-1-yl)propyl)piperidine-4-yl) acetamide trifluoroacetate 
• 359878-20-9 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-(1-cyclohexylmethylpiperidin-4-yl) acetamide hydrochloride 
• 359879-04-2 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(2-methylthiazol-4-ylmethyl) piperidin-4-yl] acetamide hydrochloride 
• 359879-55-3 N-((3-hydroxy-4-methylphenyl)methyl)-4-amino-1-methylpiperidine 
• 41838-46-4 4-Amino-1-methylpiperidine 
• 1091682-07-3 (R)-N-((S)-1-{4-[benzyloxycarbonyl-(4-methyl-benzyl)-amino]-piperidine-1-carbonyl}-2,2-dimethyl-propyl)-3-cyclopentylmethyl-succinic acid 
• 1091682-04-0 (R)-2-cyclopentylmethyl-N₁-{(S)-2,2-dimethyl-1-[4-(4-methyl-benzylamino)-piperidine-1-carbonyl]-propyl}-N₄-hydroxy-succinamide 
• 1091681-70-7 (4-methyl-benzyl)-piperidin-4-yl-carbamic acid benzyl ester hydrochloride 
• 1091681-72-9 [1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-piperidin-4-yl]-(4-methyl-benzyl)-carbamic acid benzyl ester 
• 1091681-67-2 [1-((S)-2-amino-3,3-dimethyl-butyryl)-piperidin-4-yl]-(4-methyl-benzyl)-carbamic acid benzyl ester hydrochloride 
• 1091682-12-0 (1-{(S)-2-[(R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-propionylamino]-3,3-dimethyl-butyryl}-piperidin-4-yl)-(4-methyl-benzyl)-carbamic acid benzyl ester 
• 1091682-11-9 (R)-2-cyclopentylmethyl-N-{(S)-2,2-dimethyl-1-[4-(4-methyl-benzylamino)-piperidine-1-carbonyl]-propyl}-3-(formyl-hydroxy-amino)-propionamide 

Relevant articles and documents

Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria

We have previously reported amidopiperidine derivatives as a novel peptide deformylase (PDF) inhibitor and evaluated its antibacterial activity against Gram-positive bacteria, but poor pharmacokinetic profiles have resulted in low efficacy in in vivo mouse models. In order to overcome these weaknesses, we newly synthesized aminopiperidine derivatives with remarkable antimicrobial properties and oral bioavailability, and also identified their in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and penicillin-resistant Streptococcus pneumoniae (PRSP).

A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF

The present invention relates to the novel antibacterial compounds having potent antibacterial activity as inhibitors of peptide deformylase. This invention further relates to pharmaceutically acceptable salts thereof, to processes for their preparation, and to pharmaceutical compositions containing them as an active ingredient.

USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS

Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.